Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Abstract Background The ORIENT-15 double-blind randomized controlled trial demonstrated that the addition of sintilimab to chemotherapy for locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) resulted in better clinical outcomes. In this analysis, we sought to evaluate the cost...

Full description

Saved in:
Bibliographic Details
Main Authors: Cuicui Yu, Yingqi Wu, Yadi Geng, Hui Yan, Pengli Zhu, Peng Ji, Fei Wu, Lijuan Ning, Yubin Feng, Aizong Shen
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Health Economics Review
Subjects:
Cost-effectiveness analysis
ORIENT-15 trial
Oesophageal squamous cell carcinoma
Sintilimab
First-line treatment
Online Access:https://doi.org/10.1186/s13561-024-00588-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13561-024-00588-2

Similar Items